hTR Inhibitors
1 drugsAbout hTR
Human telomerase RNA component (hTR) is the RNA subunit of the telomerase ribonucleoprotein complex, essential for maintaining telomere length. Telomerase prevents telomere shortening during cell division, a process crucial for genome stability. Reactivation of telomerase in cancer cells allows them to bypass normal cell division limits.
hTR is a compelling oncology target due to its role in cancer cell immortality. There is currently no genetic evidence directly linking hTR mutations to specific diseases, suggesting therapeutic strategies focus on modulating overall telomerase activity.
hTR is targeted by one FDA-approved drug, RYTELO (small molecule), developed by GERON for oncology indications. RYTELO received its first approval in 2024, marking the beginning of hTR-targeted therapies.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Recurrent Childhood Acute Myeloid Leukemia with only 1 trials.
Top hTR Drugs
GERON is currently the only company with an approved hTR-targeting drug.
The market is highly concentrated, suggesting high barriers to entry or a first-mover advantage for GERON.
hTR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets hTR, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches like oligonucleotides or gene therapies.
hTR Clinical Trials 17 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 2 | 2 | 3 | 50% |
| Phase 2 | 9 | 4 | 2 | 3 | 67% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
hTR Drug Approval Timeline (2024 - 2024)
RYTELO was first approved in 2024, marking the beginning of hTR-targeted therapies.
The recent approval suggests a growing interest in hTR as a target, but it is too early to assess market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 14 clinical trials targeting hTR.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities